ACC.26丨聚焦血脂異常領(lǐng)域，盤點即將公布的最新研究進(jìn)展！

血脂異常作為心血管疾病的重要危險因素，與動脈粥樣硬化、冠心病、腦卒中等多種嚴(yán)重疾病的發(fā)生發(fā)展緊密相關(guān)，嚴(yán)重威脅著人們的健康。近年來，血脂領(lǐng)域的研究不斷取得新突破，從新型降脂藥物的研發(fā)到血脂管理策略的優(yōu)化，每一項進(jìn)展都備受關(guān)注。北京時間3月28日至30日，備受矚目的ACC.26學(xué)術(shù)會議將在美國新奧爾良盛大召開。作為心血管領(lǐng)域的國際盛會，本次大會眾多國際研究者發(fā)布了針對血脂異常的最新研究成果，POCKETIN特別匯集整理了相關(guān)日程，一起來先睹為快！

03月28日

1006. New Frontiers in Lipid Management
北京時間：22:42
EFFICACY AND SAFETY OF OLEZARSEN FOR THE MANAGEMENT OF DYSLIPIDEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLEDTRIALS
Olezarsen治療血脂異常的療效與安全性：隨機對照試驗的系統(tǒng)評價與薈萃分析

S. Neppala

北京時間：23:18
LIPOPROTEIN(A)-TARGETED THERAPIES VERSUS PLACEBO/STANDARD CARE IN ASCVD: EFFECTS ON MACE, LP(A) REDUCTION AND SAFETY — SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS
脂蛋白(a)靶向治療對比安慰劑/標(biāo)準(zhǔn)治療在動脈粥樣硬化性心血管疾病中的應(yīng)用：對主要不良心血管事件、脂蛋白(a)降低及安全性的影響——隨機對照試驗的系統(tǒng)評價與薈萃分析

N. Lanka

1302. Cardiovascular Disease Prevention 01
北京時間：22:30
REAL-WORLD UTILIZATION AND PERSISTENCE OF LIPID-LOWERING THERAPIES AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI)
經(jīng)皮冠狀動脈介入治療后降脂治療的真實世界使用情況與持續(xù)性

Muhammad Raffey Shabbir

北京時間：22:30
IMPACT OF LOMITAPIDE ON LIPID PROFILES IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS
洛美他派對純合子家族性高膽固醇血癥血脂譜的影響：一項系統(tǒng)評價與單組薈萃分析

A. Akoum

北京時間：22:30
EFFICACY AND SAFETY OF RECATICIMAB FOR LDL-C AND LIPOPROTEIN(A) REDUCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
瑞卡西單抗降低低密度脂蛋白膽固醇和脂蛋白(a)的療效與安全性：一項系統(tǒng)評價與薈萃分析

S. Fausto Girón

北京時間：22:30
SGLT2 INHIBITORS, BUT NOT DPP4 INHIBITORS,LOWER LDL-C ANDIMPROVE OUTCOMES IN PATIENTSWITH DIABETES AND CORONARY ARTERY DISEASE
SGLT2抑制劑，而非DPP4抑制劑，可降低糖尿病合并冠狀動脈疾病患者的低密度脂蛋白膽固醇并改善結(jié)局

A. Theertham

1305. Congenital Heart Disease 01
北京時間：22:30
EXPLORING THE RELATIONSHIP BETWEEN ATRIAL REFRACTORINESS, DYSLIPIDEMIA AND ATRIAL FIBRILLATION IN CHILDREN AND YOUNG PERSONS
探討兒童與青少年心房不應(yīng)期、血脂異常及心房顫動之間的關(guān)系

S. P. Behere

1310. Vascular Diseases 01
北京時間：22:30
DOSE-RESPONSE RELATIONSHIP AND EFFICACY OF EVINACUMAB FOR REFRACTORY AND GENETIC DYSLIPIDEMIAS A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
依維蘇單抗在難治性及遺傳性血脂異常中的劑量-反應(yīng)關(guān)系及療效：隨機對照試驗的系統(tǒng)評價與薈萃分析

Syed Habib

1323. Heart Failure and Cardiomyopathies 01
北京時間：22:30
GLP-1 RECEPTOR AGONISTS IN HEART FAILURE WITH REDUCED/MILDLY REDUCED EF: 5-YEAR OUTCOMES AND EFFECT MODIFICATION BY OBESITY AND ETHNICITY
GLP-1受體激動劑在射血分?jǐn)?shù)降低/輕度降低的心力衰竭中的應(yīng)用：5年結(jié)局及肥胖與種族的效應(yīng)修飾作用

H. Agarwal

03月29日

1019. Cellular Biology of Atherosclerotic Plaque
北京時間：00:36
OXIDIZED LDL TRIGGERS PYROPTOSIS IN VASCULAR SMOOTH MUSCLE CELLS AND SALIDROSIDE TREATMENT MITIGATES THIS PATHWAY TO IMPROVE PLAQUE STABILITY
氧化低密度脂蛋白觸發(fā)血管平滑肌細(xì)胞發(fā)生細(xì)胞焦亡，而紅景天苷治療可減輕該通路以改善斑塊穩(wěn)定性

許恒偉 陜西省人民醫(yī)院

北京時間：00:48
IMPAIRED EFFEROCYTOSIS IN RESPONSE TO LOW-DENSITY LIPID AND LOW SHEAR STRESS IN AN IN-VITROMODEL OF ATHEROSCLEROSIS
在動脈粥樣硬化體外模型中，對低密度脂蛋白和低剪切應(yīng)力應(yīng)答的胞葬作用受損

Ruben Tapia-Orihuela

1324. CV Team 02
北京時間：00:00
FLORIDA CARDIOVASCULAR QUALITY NETWORK; THE CENTRAL ROLE OF ADVANCED PRACTICE PROFESSIONALS TO ACHIEVE A SUSTAINED TWO YEAR IMPROVEMENT IN CARDIOVASCULAR RISK IN HIGH RISK HYPERLIPIDEMIA PATIENTS
佛羅里達(dá)心血管質(zhì)量網(wǎng)絡(luò)：高級執(zhí)業(yè)醫(yī)師在高風(fēng)險高脂血癥患者中實現(xiàn)心血管風(fēng)險持續(xù)兩年改善的核心作用

Kim Seals

1325. Featured Fields 02
北京時間：00:00
CHRONOLOGICAL AGING AND PROGRESSION OF CORONARY ARTERY DISEASE: INSIGHTS FROM POOLED IVUS TRIALS OF LIPID-LOWERING THERAPIES
時序性衰老與冠狀動脈疾病進(jìn)展：來自降脂治療匯總血管內(nèi)超聲試驗的見解

A. Damluji

1326. Cardiovascular Disease Prevention 02
北京時間：00:00
THE RELATIONSHIP BETWEEN CYTOKINES AND LIPIDS WITH MRI-DERIVED MEASURES OF CARDIAC MORPHOLOGY IN MEXICAN AMERICANS
墨西哥裔美國人中細(xì)胞因子和血脂與磁共振成像衍生的心臟形態(tài)測量指標(biāo)之間的關(guān)系

V. O’Brien

北京時間：00:00
EFFECT OF AN EMR-EMBEDDED IN-HOSPITAL CLINICAL PATHWAY ON LIPID MANAGEMENT AFTER ACUTE CORONARY SYNDROME
嵌入電子病歷的院內(nèi)臨床路徑對急性冠狀動脈綜合征后血脂管理的影響

Tatsuhiro Kataoka

北京時間：00:00
A SINGLE-CENTER RETROSPECTIVE STUDY OF THE ASSOCIATION BETWEEN LIPOPROTEIN(A) AND LIPID LEVELS IN A PEDIATRIC POPULATION
脂蛋白(a)與兒童人群血脂水平關(guān)聯(lián)的單中心回顧性研究

Dorota Gruber

1328. Ischemic Heart Diseases 02
北京時間：00:00
RACIAL/ETHNIC AND SEX DISPARITIES IN LDL-C TESTING FREQUENCY POST CORONARY ARTERY BYPASS GRAFTING (CABG): INSIGHTS FROM A LARGE INTEGRATED, DIVERSE HEALTHCARE SYSTEM
冠狀動脈旁路移植術(shù)后低密度脂蛋白膽固醇檢測頻率的種族/民族和性別差異：來自一個大型綜合性多元化醫(yī)療系統(tǒng)的見解

Janine Yang

1332. Coronary, Peripheral and Structural Interventions 02
北京時間：00:00
REFERENCE ZONE LIPID PLAQUE AND TIME TO RESTENOSIS PREDICT NEOATHEROSCLEROSIS ON OCT
參照區(qū)脂質(zhì)斑塊和再狹窄時間預(yù)測光學(xué)相干斷層掃描上的新發(fā)動脈粥樣硬化

Nicholas Olivieri

1337. Complex Clinical Cases: Cardiovascular Disease Prevention 02
北京時間：00:00
LACK OF RESPONSE TO INCLISIRAN IN HIGH-RISK PATIENTS WITH ADVERSE EFFECTS TO TRADITIONAL LIPID-LOWERING THERAPIES
高危患者對英克司蘭無反應(yīng)并對傳統(tǒng)降脂治療產(chǎn)生不良反應(yīng)

Patricia Machado

1034. Cardiac Imaging Research: From Data to Decision
北京時間：01:42
PHYSIOLOGICAL CHANGES IN NON-OBSTRUCTIVE CORONARY LESIONS BEFORE AND AFTER MAXIMAL LIPID LOWERING THERAPY USING AI BASED OPTICAL FLOW RATIO: INSIGHTS FROM YELLOW III STUDY
使用基于人工智能的光學(xué)血流比評估最大降脂治療前后非阻塞性冠狀動脈病變的生理變化：來自YELLOW III研究的見解

P. Chenniganahosahalli

1038. Drug Therapy in Valvular Heart Disease: Evaluating Evidence for Disease Modification and Outcome Improvement
北京時間：01:30
ASPIRIN THERAPY IN INDIVIDUALS WITH ELEVATED OXIDIZED PHOSPHOLIPIDS AND RISK OF CALCIFIC AORTIC VALVE DISEASE: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS
阿司匹林治療在氧化磷脂升高個體中的應(yīng)用與鈣化性主動脈瓣疾病風(fēng)險：多民族動脈粥樣硬化研究

A. C. Razavi

1348. CV Team 03
北京時間：01:30
FROM GRAFT TO GRAPH: REAL WORLD PRACTICES IN LIPID LOWERING AMONG TRANSPLANT PATIENTS
從移植到圖譜：移植患者中降脂治療的真實世界實踐

S. F. Weintraub

228. Bold Moves into the Future: The 2026 ACC/AHA Multisociety Guideline For Management of Dyslipidemia
北京時間：02:41
A New Era in Risk Assessment: The PREVENT Calculator in Dyslipidemia Management
風(fēng)險評估的新紀(jì)元：PREVENT計算器在血脂異常管理中的應(yīng)用

Donald M. Lloyd-Jones

北京時間：03:03
The Risk Continuum: Lipid Management From Start to Finish
風(fēng)險連續(xù)體：從頭到尾的脂質(zhì)管理

Pamela Bowe Morris

1052. Targeting Lp(a) to Reduce Risk
北京時間：03:00
LP(A)-CORRECTED APOB-P/HDL-P RATIO STRONGLY PREDICTS ASCVD EVENTS: UK BIOBANK INSIGHTS
LP(A)-校正的APOB-P/HDL-P比值可強效預(yù)測動脈粥樣硬化性心血管疾病事件：來自英國生物樣本庫的見解

E. S. Epstein

北京時間：03:12
LIPOPROTEIN(A), OXIDIZED PHOSPHOLIPIDS AND TENSILE CLOT STRENGTH MEASURED BY THROMBOELASTOGRAPHY IN PATIENTS UNDERGOING PERCUTANEOUS INTERVENTION
接受經(jīng)皮介入治療患者的脂蛋白(a)、氧化磷脂與血栓彈力圖測定的血栓拉伸強度

Paul Gurbel

1060. ACC Complex Clinical Cases: Cardiovascular Disease Prevention
北京時間：03:48
ACUTE-ONSET CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY PRECIPITATED BY PCSK9 INHIBITOR DOSE ESCALATION: A COMPLEX CASE IN DYSLIPIDEMIA MANAGEMENT
由PCSK9抑制劑劑量遞增引發(fā)的急性發(fā)作性慢性炎性脫髓鞘性多發(fā)性神經(jīng)?。阂焕龔?fù)雜的血脂異常管理案例

C. Stephenson-Moe

1374. Cardiovascular Disease Prevention 04
北京時間：03:00
LIPID SUBFRACTIONS AND SUBCLINICAL ATHEROSCLEROSIS PROGRESSION: A LIPIDOMICS APPROACH TO CARDIOVASCULAR RISK IN THE BRAZILIAN LONGITUDINAL STUDY OF ADULT HEALTH ELSA BRAZIL
脂質(zhì)亞組分與亞臨床動脈粥樣硬化進(jìn)展：巴西成人健康縱向研究中脂質(zhì)組學(xué)方法對心血管風(fēng)險的研究

L. F. Carvalho

北京時間：03:00
WOMEN ARE LESS LIKELY THAN MEN TO RECEIVE ADD-ON NONSTATIN LIPID-LOWERING THERAPY (LLT) AND TO ADHERE TO LLT: A SYSTEMATIC REVIEW
女性接受附加非他汀類降脂治療及堅持該治療的可能性低于男性：一項系統(tǒng)評價

Alejandro Victores

1376. Ischemic Heart Diseases 04
北京時間：03:00
LIPID PROFILES UNDERLIE PROTECTION FROM ATHEROSCLEROSIS SEEN IN PATIENTS WITH ASCENDING THORACIC AORTIC ANEURYSMS
血脂譜是升主動脈瘤患者對動脈粥樣硬化具有保護(hù)作用的基礎(chǔ)

Asanish Kalyanasundaram

北京時間：03:00
PATTERNS AND CHARACTERISTICS OF ASCVD EVENTS IN PATIENTS ≥65 YEARS WITH LP(A) ≥50 MG/DL: PREMATURE, AVERAGE, AND NO EVENTS
65歲及以上脂蛋白(a) ≥50 mg/dL患者動脈粥樣硬化性心血管疾病事件的模式與特征：早發(fā)、平均發(fā)生與無事件

V. T. Le

1380. Coronary, Peripheral and Structural Interventions 04
北京時間：03:00
EFFECT OF LIPID-LOWERING THERAPY ON INTRACORONARY IMAGING ENDPOINTS FOLLOWING PACLITAXEL-COATED BALLOON TREATMENT
降脂治療對紫杉醇涂層球囊治療后冠狀動脈內(nèi)影像學(xué)終點的影響

Tamara Dijkstra

1385. Complex Clinical Cases: Cardiovascular Disease Prevention 04
北京時間：03:00
ROBUST LP(A) REDUCTION WITH COMBINED TOCILIZUMAB AND INCLISIRAN IN A HIGH-RISK INFLAMMATORY PATIENT
聯(lián)合托珠單抗與英克司蘭在高風(fēng)險炎癥患者中實現(xiàn)脂蛋白(a)的顯著降低

Robert Luceri

1069. Next-Generation Lipid Treatement Options
北京時間：04:54
EFFECTIVENESS OF LDL-C LOWERING WITH ALIROCUMAB AND INCLISIRAN IN A CLINICAL PRACTICE SETTING
阿利西尤單抗和英克司蘭在臨床實踐環(huán)境中降低低密度脂蛋白膽固醇的有效性

M. Banach

1397. Featured Fields 05
北京時間：04:30
LIPID PROFILES AND FAST FOOD CONSUMPTION PATTERNS AMONG YOUNG AND OLDER U.S. ADULTS: AN NHANES 2008-2018 ANALYSIS
美國年輕與年長成人的血脂譜和快餐消費模式：2008-2018年美國國家健康與營養(yǎng)調(diào)查分析

H. Shah

1398. Cardiovascular Disease Prevention 05
北京時間：04:30
FLORIDA CARDIOVASCULAR QUALITY NETWORK: TWO YEAR RESULTS CONFIRM A SUSTAINED IMPROVEMENT IN CARDIOVASCULAR RISK IN HIGH RISK HYPERLIPIDEMIA PATIENTS
佛羅里達(dá)心血管質(zhì)量網(wǎng)絡(luò)：兩年結(jié)果證實高風(fēng)險高脂血癥患者心血管風(fēng)險的持續(xù)改善

A. Allen Seals

北京時間：04:30
THE IMPACT OF STATIN THERAPY ON LIPID PROFILES AND ATHEROSCLEROTIC MARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS: A META-ANALYSIS
他汀類藥物治療對系統(tǒng)性紅斑狼瘡患者血脂譜和動脈粥樣硬化標(biāo)志物的影響：一項薈萃分析

Danielle Howell

北京時間：04:30
LIPOPROTEIN(A) AND OXIDIZED PHOSPHOLIPIDS-APOLIPOPROTEIN B, BIOMARKERS OF RISK IN CARDIAC TRANSPLANT OUTCOMES
脂蛋白(a)和氧化磷脂-載脂蛋白B：心臟移植結(jié)局的風(fēng)險生物標(biāo)志物

Andrew Kao

1419. Heart Failure and Cardiomyopathies 05
北京時間：04:30
HYPERLIPIDEMIA AS A PREDICTOR OF EPICARDIAL ADIPOSITY IN PATIENTS WITH HEART FAILURE WITH PRESERVED BUT NOT REDUCED EJECTION FRACTION
高脂血癥作為射血分?jǐn)?shù)保留而非降低的心力衰竭患者心外膜脂肪量的預(yù)測因子

M. C. Volk

233. New Kids on the Block in the Battle Against PAD
北京時間：05:15
Novel Lipid Therapies in PAD
外周動脈疾病中的新型脂質(zhì)療法

Naomi M. Hamburg

1084. Evolving Non-Statin Lipid Therapies
北京時間：22:54
LIPID-LOWERING EFFICACY AND SAFETY OF RECATICIMAB IN DYSLIPIDEMIA PATIENTS WITH OR WITHOUT TYPE 2 DIABETES MELLITUS: A POOLED PATIENT-LEVEL SUBGROUP ANALYSIS
瑞卡西單抗在伴或不伴2型糖尿病的血脂異常患者中的降脂療效與安全性：一項患者水平匯總的亞組分析

孫燕依 上海交通大學(xué)醫(yī)學(xué)院附屬瑞金醫(yī)院

北京時間：23:06
EFFICACY AND SAFETY OF OBICETRABIP IN REDUCING ATHEROGENIC LIPIDS: A SYSTEMATIC REVIEW AND DOSE RESPONSE META-ANALYSIS WITH TRIAL SEQUENTIAL ANALYSIS
Obicetrapib降低致動脈粥樣硬化脂質(zhì)的療效與安全性：一項系統(tǒng)評價、劑量反應(yīng)薈萃分析及試驗序貫分析

Prutha Pathak

1422. Cardiovascular Disease Prevention 06
北京時間：22:30
EFFECT OF BASELINE LIPID LEVELS OR STATIN USE ON FINERENONE TREATMENT OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES: A FIDELITY POST HOC ANALYSIS
基線血脂水平或他汀類藥物使用對慢性腎臟病合并2型糖尿病患者非奈利酮治療結(jié)局的影響：FIDELITY事后分析

A. Verma

1433. Complex Clinical Cases: Cardiovascular Disease Prevention 06
北京時間：22:30
AGGRESSIVE LIPID LOWERING IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: 29 YEARS EVENT-FREE SURVIVAL AFTER PREMATURE STEMI
雜合子家族性高膽固醇血癥的強化降脂治療：早發(fā)ST段抬高型心肌梗死后29年無事件生存

Robert Luceri, MD

北京時間：22:30
SITOSTEROLEMIA: A RARE, UNDERDIAGNOSED GENETIC DYSLIPIDEMIA
谷固醇血癥：一種罕見、未被充分診斷的遺傳性血脂異常

Boran Mao

267. From Pharm to Table: An Update on Cardiac Prevention Medications
北京時間：23:55
Tasting Menu of the Newest Lipid Medications
最新降脂藥物的品鑒菜單

Ashley Arana Waring

4505. Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
北京時間：07:30
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
隨血脂管理律動：降低動脈粥樣硬化性心血管疾病風(fēng)險的新節(jié)奏

Tyler J. Gluckman

北京時間：07:30
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
隨血脂管理律動：降低動脈粥樣硬化性心血管疾病風(fēng)險的新節(jié)奏

Viet T. Le

北京時間：07:30
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
隨血脂管理律動：降低動脈粥樣硬化性心血管疾病風(fēng)險的新節(jié)奏

Erin D. Michos

北京時間：07:30
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
隨血脂管理律動：降低動脈粥樣硬化性心血管疾病風(fēng)險的新節(jié)奏

Pam Taub

3001. Putting the Guidelines into Practice: Building a State-of-the-Art Lipid and Cardiometabolic Clinic
北京時間：07:10
Key Implementation Highlights from the 2026 Guideline on the Management of Dyslipidemia
2026年血脂異常管理指南的關(guān)鍵實施要點

Pamela Bowe Morris

北京時間：07:25
Nuts and Bolts of a Lipid and Cardio-Kidney-Metabolic Clinic
血脂與心臟-腎臟-代謝門診的基本要素

Anum Saeed

1350. Cardiovascular Disease Prevention 03
北京時間：01:30
RETHINKING RISK THRESHOLDS: LP(A) STRATIFICATION REVEALS STEPWISE RISE IN MORTALITY AND MACE
重新思考風(fēng)險閾值：脂蛋白(a)分層顯示死亡率和主要不良心血管事件呈階梯式上升

Osman Yousafzai

4002. Make It Standard: Lp(a) Integration For CV Risk Impact
北京時間：01:30
Make It Standard: Lp(a) Integration For CV Risk Impact
標(biāo)準(zhǔn)化：Lp(a) 整合對心血管風(fēng)險的影響

Christie M. Ballantyne

北京時間：01:30
Make It Standard: Lp(a) Integration For CV Risk Impact
標(biāo)準(zhǔn)化：Lp(a)整合對心血管風(fēng)險影響

Keith C. Ferdinand

北京時間：01:30
Make It Standard: Lp(a) Integration For CV Risk Impact
標(biāo)準(zhǔn)化：Lp(a)整合對心血管風(fēng)險的影響

Fatima Rodriguez

402. Driving Impact at the Point of Care: Inside the ACC’s Solution Set Strategy
北京時間：00:55
Driving Urgency in LDL Screening
推動低密度脂蛋白篩查的緊迫性

Timothy A. Dewhurst

03月30日

1446. Cardiovascular Disease Prevention 07
北京時間：00:00
ASSOCIATION BETWEEN LDL-C LOWERING AND REDUCED RISK OF CARDIOVASCULAR EVENTS: AN UPDATED SYSTEMATIC REVIEW AND META-REGRESSION
低密度脂蛋白膽固醇降低與心血管事件風(fēng)險降低之間的關(guān)聯(lián)：一項更新的系統(tǒng)評價與元回歸分析

X. Zhang

1448. Ischemic Heart Diseases 07
北京時間：00:00
THE INCOMPLETE PREVENTION STORY: TRENDS IN LIPID PROFILES AND THERAPY PATTERNS BEFORE FIRST ACUTE MYOCARDIAL INFARCTION IN THE BMC2 REGISTRY
不完全的預(yù)防故事：BMC2登記研究中首次急性心肌梗死前血脂譜和治療模式的趨勢

M. Albdewi

1457. Complex Clinical Cases: Cardiovascular Disease Prevention 07
北京時間：00:00
STEPWISE COMBINATION THERAPY ACHIEVING SIGNIFICANT LDL-CHOLESTEROL REDUCTION IN SEVERE HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
逐步聯(lián)合治療在重度純合子家族性高膽固醇血癥中實現(xiàn)顯著的低密度脂蛋白膽固醇降低

Christine Kong

108. Cardiovascular Update For the Clinician I: A Symposium by Valentin Fuster
北京時間：01:51
Solving Statin Intolerance and Lp(a) Challenges: The Five Advances, Including RNA Agents With Infrequent SC Injections
解決他汀不耐受與脂蛋白(a)挑戰(zhàn)：五項進(jìn)展，包括間歇皮下注射的RNA藥物

Robert S. Rosenson

1116. Environment Influences on Prevention
北京時間：01:42
PM2.5 ACCELERATES ATHEROSCLEROSIS VIA ROS-INDUCED LDL OXIDATION AND ENDOTHELIAL PROGENITOR CELL DEPLETION: PROTECTIVE ROLE OF N-ACETYLCYSTEINE
PM2.5通過活性氧誘導(dǎo)的低密度脂蛋白氧化和內(nèi)皮祖細(xì)胞耗竭加速動脈粥樣硬化：N-乙酰半胱氨酸的保護(hù)作用

Yuqi Cui

1469. Cardiovascular Disease Prevention 08
北京時間：01:30
TRENDS AND DEMOGRAPHIC DISPARITIES IN HYPERTENSION AND DYSLIPIDEMIA-RELATED MORTALITY IN OLDER AMERICAN ADULTS, 1999-2023
1999-2023年美國老年人高血壓和血脂異常相關(guān)死亡率的趨勢與人口統(tǒng)計學(xué)差異

R. Ochani

北京時間：01:30
FINDINGS FROM THE LISTEN-LDL-US (LIPID LOWERING THERAPY INSIGHTS PATIENT SURVEY ON TREATMENT EXPERIENCES AND NEEDS IN THE UNITED STATES) STUDY
來自LISTEN-LDL-US（美國降脂治療患者體驗與需求洞察調(diào)查）研究的發(fā)現(xiàn)

Alejandro Victores

北京時間：01:30
COMPARATIVE EFFECTIVENESS OF CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY WITH OR WITHOUT AI-PLAQUE ANALYSIS AND STRESS TESTING ON LIPID LOWERING AFTER ONE YEAR: A PRIMARY ANALYSIS OF THE DECIDE (AI-DERIVED PLAQUE QUANTIFICATION: CTA AND AI-QCPA FOR DETERMINING EFFECTIVE CAD MANAGEMENT) REGISTRY
冠狀動脈CT血管成像聯(lián)合或不聯(lián)合人工智能斑塊分析及負(fù)荷試驗對一年后降脂效果的比較：DECIDE（人工智能衍生斑塊量化：用于確定有效冠狀動脈疾病管理的CTA與AI-QCPA）登記研究的初步分析

Sarah Rinehart

1473. Multimodal Imaging 08
北京時間：01:30
PHYSIOLOGICAL CHANGES IN NON-OBSTRUCTIVE CORONARY LESIONS BEFORE AND AFTER MAXIMAL LIPID-LOWERING THERAPY USING AI-BASED MURRAY LAW-DERIVED QUANTITATIVE FLOW RATIO (μFR): INSIGHTS FROM THE YELLOW III STUDY
使用基于人工智能的默里定律衍生的定量血流比評估最大降脂治療前后非阻塞性冠狀動脈病變的生理變化：來自YELLOW III研究的見解

P. Chenniganahosahalli

1480. Complex Clinical Cases: Cardiovascular Disease Prevention 08
北京時間：01:30
WHEN LIPIDS MISLEAD: A CARDIOLOGIST’S DILEMMA IN REFRACTORY HYPERTRIGLYCERIDEMIA
當(dāng)脂質(zhì)誤導(dǎo)：一位心臟病專家在難治性高甘油三酯血癥中的困境

Kristina Golovataya

305. When is Exercise the Risk? And When is It the Rx?
北京時間：03:20
Managing Hyperlipidemia in the Athlete
運動員的高脂血癥管理

James S. Guseh

1133. Social Factors Driving Cardiovascular Outcomes
北京時間：03:12
RELATIONSHIP BETWEEN GLYCEMIC CONTROL AND LIPID ABNORMALITIES IN FOOD INSECURE POPULATIONS
食物不安全人群中血糖控制與脂質(zhì)異常之間的關(guān)系

Tina Ting, MPH

1493. Cardiovascular Disease Prevention 09
北京時間：03:00
THE APOB-LDL-C CONTINUUM: INSIGHTS INTO TESTING TRENDS AND DISCORDANCE FROM A LARGE-SCALE LABORATORY STUDY
載脂蛋白B-低密度脂蛋白膽固醇連續(xù)譜：來自大規(guī)模實驗室研究的檢測趨勢與不一致性的見解

Anjali Bhatla

北京時間：03:00
LDL CHOLESTEROL, NON-HDL CHOLESTEROL, APOLIPOPROTEIN B AND 30-YEAR RISK OF CARDIOVASCULAR DISEASE AMONG HEALTHY WOMEN
健康女性中低密度脂蛋白膽固醇、非高密度脂蛋白膽固醇、載脂蛋白B與30年心血管疾病風(fēng)險的關(guān)系

Ask Nordestgaard

北京時間：03:00
PREVALENCE AND PRACTICE OF LP(A) TESTING IN HIGH RISK POPULATIONS AT THE UNIVERSITY OF KANSAS MEDICAL CENTER
堪薩斯大學(xué)醫(yī)學(xué)中心高風(fēng)險人群中脂蛋白(a)檢測的普遍性與實踐

P. M. Moriarty

1495. Ischemic Heart Diseases 09
北京時間：03:00
CORONARY CT ANGIOGRAPHY FINDINGS DRIVE LIPID-LOWERING THERAPY INITIATION AND INTENSIFICATION IN CLINICAL PRACTICE
冠狀動脈CT血管成像結(jié)果推動臨床實踐中降脂治療的啟動與強化

W. van de Vijver

1504. Complex Clinical Cases: Cardiovascular Disease Prevention 09
北京時間：03:00
HIDING IN PLAIN SIGHT: PARTIAL LIPODYSTROPHY WITH SEVERE DYSLIPIDEMIA, STATIN INTOLERANCE, AND PREMATURE CORONARY ARTERY DISEASE IN A TRIATHLETE
隱藏在明處：一名鐵人三項運動員的部分脂肪萎縮伴嚴(yán)重血脂異常、他汀不耐受及早發(fā)冠狀動脈疾病

C. S. Agu

1506. Complex Clinical Cases: Ischemic Heart Diseases 09
北京時間：03:00
WHEN GAINS BECOME LOSSES: EXOGENOUS TESTOSTERONE AND CARNIVORE DIET LINKED TO SEVERE HYPERLIPIDEMIA AND PREMATURE CORONARY ARTERY DISEASE
當(dāng)獲益轉(zhuǎn)為損失：外源性睪酮與肉食飲食與嚴(yán)重高脂血癥及早發(fā)冠狀動脈疾病相關(guān)

Mary Trejo Hernandez

1517. Cardiovascular Disease Prevention 10
北京時間：04:30
THE MI-TO-CVD RATIO IN LIPID-LOWERING TRIALS: EVOLVING PATTERNS AND IMPLICATIONS FOR FUTURE STUDY DESIGN
降脂試驗中的心肌梗死與心血管疾病比值：演變模式及對未來研究設(shè)計的意義

R. Nair

1521. Multimodal Imaging 10
北京時間：04:30
AI-BASED ANGIOGRAPHY-DERIVED RADIAL WALL STRAIN IN NON-OBSTRUCTIVE CORONARY LESIONS BEFORE AND AFTER MAXIMAL LIPID-LOWERING THERAPY: INSIGHTS FROM THE YELLOW III STUDY
基于人工智能的血管造影衍生的非阻塞性冠狀動脈病變在最大降脂治療前后徑向壁應(yīng)變：來自YELLOW III研究的見解

P. Chenniganahosahalli

北京時間：04:30
IMPACT OF MAXIMAL LIPID LOWERING THERAPY ON THE PHYSIOLOGICAL DISEASE PATTERN USING AI BASED VIRTUAL μFR PULLBACK CURVE: INSIGHTS FROM THE YELLOW III STUDY
使用基于人工智能的虛擬μFR回撤曲線評估最大降脂治療對生理疾病模式的影響：來自YELLOW III研究的見解

P. Chenniganahosahalli

北京時間：04:30
INTRACORONARY IMAGING INSIGHTS INTO THE MORPHOLOGY OF CALCIFIED NODULES BEFORE AND AFTER MAXIMAL LIPID LOWERING THERAPY: A SUBSTUDY OF YELLOW III
最大降脂治療前后鈣化結(jié)節(jié)形態(tài)的冠狀動脈內(nèi)影像學(xué)見解：YELLOW III研究的子研究

Pruthvi Chenniganahosahalli

1528. Complex Clinical Cases: Cardiovascular Disease Prevention 10
北京時間：04:30
A CASE OF REMARKABLE REDUCTION IN LDL FROM AKKERMANSIA PROBIOTIC
一例阿克曼氏菌益生菌顯著降低低密度脂蛋白膽固醇的病例

J. Helali

北京時間：04:30
THE PERFECT STORM: TACKLING THE TRIPLE THREAT OF LIPID DISORDERS, TYPE 1 DIABETES, AND AN INFLAMMATORY DISORDER IN A YOUNG WOMAN
完美風(fēng)暴：應(yīng)對年輕女性中脂質(zhì)紊亂、1型糖尿病和炎癥性疾病的三重威脅

J. Hicks

北京時間：04:30
BEATING THE ODDS: ADVANCED LIPID THERAPY ACHIEVES CONTROL IN CHYLOMICRONEMIA
戰(zhàn)勝逆境：先進(jìn)的脂質(zhì)治療實現(xiàn)乳糜微粒血癥的控制

Flavia Tejada

1538. Heart Failure and Cardiomyopathies 10
北京時間：04:30
TRENDS IN HEART FAILURE AND HYPERLIPIDEMIA-RELATED MORTALITY IN THE UNITED STATES: A RETROSPECTIVE ANALYSIS OF CDC WONDER FROM 1999 TO 2019
美國心力衰竭與高脂血癥相關(guān)死亡率的趨勢：1999年至2019年CDC WONDER數(shù)據(jù)庫的回顧性分析

A. Shabbir

1163. Advancing Lipid Management and Prevention in IHD
北京時間：22:30
ACHIEVED LDL-C IS ASSOCIATED WITH SAPHENOUS VEIN GRAFT PATENCY IN THE NEWTON-CABG CARDIOLINK-5 STUDY
在NEWTON-CABG CARDIOLINK-5研究中，達(dá)到的低密度脂蛋白膽固醇水平與大隱靜脈橋血管通暢性相關(guān)

Michael Szarek

北京時間：22:54
REAL-WORLD GAPS IN PRIMARY PREVENTION AND LIPID CONTROL AMONG PATIENTS PRESENTING WITH THEIR FIRST ACUTE MYOCARDIAL INFARCTION: INSIGHTS FROM THE NCDR CHEST PAIN-MI REGISTRY
首次急性心肌梗死患者在初級預(yù)防和血脂控制方面的真實世界差距：來自NCDR胸痛-心肌梗死登記研究的見解

Mohammed Essa

北京時間：23:06
RAPIDLY ESCALATED LIPID-LOWERING THERAPY EFFECTIVENESS IN PLAQUE STABILIZATION IN PATIENTS WITH ELEVATED LIPOPROTEIN(A)
快速升級的降脂治療在脂蛋白(a)升高患者中穩(wěn)定斑塊的有效性

Karlis Trusinskis

1164. Expanding Evidence for Nutrient Stimulated Hormone Therapies
北京時間：22:54
EFFECT OF ORFORGLIPRON, A NOVEL ORAL GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST, ON LIPID PANEL AND BLOOD PRESSURE: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
奧格列龍一種新型口服胰高血糖素樣肽-1受體激動劑，對血脂譜和血壓的影響：隨機對照試驗的薈萃分析

S. Kommu

1165. Lipid Control in Real-World Practice
北京時間：22:30
POST-MI LIPID MANAGEMENT: A PRACTICE PATTERN ANALYSIS OF THERAPY ESCALATION AND MONITORING GAPS IN CARE
心肌梗死后血脂管理：治療升級與護(hù)理監(jiān)測缺口的實踐模式分析

S. Khetrapal

北京時間：23:06
REAL-WORLD LIPID-LOWERING EFFICACY AND GOAL ATTAINMENT WITH ATORVASTATIN/EZETIMIBE FIXED-DOSE COMBINATION THERAPY
阿托伐他汀/依折麥布固定劑量聯(lián)合治療的真實世界降脂療效及目標(biāo)達(dá)成情況

Byung Gyu Kim

北京時間：23:18
LDL-C LOWERING AND ASSOCIATED RISK REDUCTION OF MYOCARDIAL INFARCTION AND STROKE-RELATED HOSPITALIZATIONS IN PATIENTS WITH ASCVD AND DIABETES
降低低密度脂蛋白膽固醇及其與動脈粥樣硬化性心血管疾病和糖尿病患者心肌梗死及卒中相關(guān)住院風(fēng)險降低的關(guān)聯(lián)

R. Jin

1541. Cardiovascular Disease Prevention 11
北京時間：22:30
PREVALENCE AND PATIENT CHARACTERISTICS OF PATIENTS WITH EXTREMELY HIGH ≥ 400 LDL-C LEVELS IN A LARGE INTEGRATED HEALTHCARE SYSTEM
大型綜合醫(yī)療系統(tǒng)中極高（≥ 400 mg/dL）低密度脂蛋白膽固醇水平患者的患病率及患者特征

J. S. Rana

1552. Complex Clinical Cases: Cardiovascular Disease Prevention 11
北京時間：22:30
WHEN LDL-C LIES - LIPOPROTEIN X MASQUERADING AS SEVERE HYPERCHOLESTEROLEMIA
當(dāng)?shù)兔芏戎鞍啄懝檀颊f謊時——脂蛋白X偽裝成嚴(yán)重高膽固醇血癥

R. Zhang

1562. Heart Failure and Cardiomyopathies 11
北京時間：22:30
EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION IN PATIENTS WITH OBESITY AND TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
GLP-1受體激動劑對肥胖合并2型糖尿病患者輕度降低或保留射血分?jǐn)?shù)的心力衰竭的影響：一項系統(tǒng)評價與薈萃分析

B. Jeswani

276. Featured Clinical Research III
北京時間：01:35
Role Of Screening With Coronary Computed Tomography Angiography In Lipid Management In An Asymptomatic Chinese Population: A Community-based, Parallel-group, Open-label, Randomized Clinical Trial (RESPECT2)
冠狀動脈CT血管造影篩查在無癥狀中國人群血脂管理中的作用：一項基于社區(qū)的、平行組、開放標(biāo)簽、隨機臨床試驗（RESPECT2）

郭翔 中國人民解放軍東部戰(zhàn)區(qū)總醫(yī)院

1471. Ischemic Heart Diseases 08
北京時間：01:30
LIPID-LOWERING EFFICACY AND SAFETY OF OBICETRAPIB: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Obicetrapib的降脂療效與安全性：一項隨機對照試驗的薈萃分析

Mariana Adieb

4014. Elevated Lp(a): Implications For Patient Risk Assessment
北京時間：03:45
Elevated Lp(a): Implications For Patient Risk Assessment
升高的脂蛋白(a)：對患者風(fēng)險評估的意義

Payal Kohli

北京時間：03:45
Elevated Lp(a): Implications For Patient Risk Assessment
升高的脂蛋白(a)：對患者風(fēng)險評估的意義

Sanjay Kaul

03月31日

1179. Improved Detection of ACS and CAD: Tests & Biomarkers
北京時間：00:24
CIRCULATING PLASMA MICRORNA PANEL FOR THE DETECTION OF LIPID-RICH CORONARY PLAQUES IN PATIENTS WITH EARLY-ONSET CORONARY ARTERY DISEASE.
用于檢測早發(fā)冠狀動脈疾病患者富脂質(zhì)冠狀動脈斑塊的血漿微小RNA組合

Evija Kana?niece

1180. Linking Lipid Metrics to CVD Risks
北京時間：00:00
CARDIOVASCULAR EVENTS IN PEOPLE WITH NORMAL LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS BUT DISCORDANTLY HIGH LEVELS OF SMALL/MEDIUM LDL PARTICLES
低密度脂蛋白膽固醇水平正常但小/中密度低密度脂蛋白顆粒水平不一致偏高的個體的心血管事件

Amand Schmidt

北京時間：00:24
BEYOND LDL CHOLESTEROL: TG/HDL-C RATIO AS A MARKER OF CARDIOVASCULAR RISK IN PEOPLE LIVING WITH HIV
超越低密度脂蛋白膽固醇：甘油三酯/高密度脂蛋白膽固醇比值作為HIV感染者的心血管風(fēng)險標(biāo)志物

Kathleen Ebersol

北京時間：00:48
IMPACT OF LDL-C AND APOLIPOPROTEIN B LEVEL DISCORDANCE AND ASSOCIATED LIPOPROTEIN PARTICLE ALTERATIONS ON CARDIOVASCULAR OUTCOMES IN A LARGE PRIMARY PREVENTION POPULATION
低密度脂蛋白膽固醇與載脂蛋白B水平不一致及相關(guān)脂蛋白顆粒改變對大規(guī)模一級預(yù)防人群心血管結(jié)局的影響

Yuan Du 中國醫(yī)學(xué)科學(xué)院阜外醫(yī)院

1565. Cardiovascular Disease Prevention 12
北京時間：00:00
EFFICACY AND SAFETY OF ONGERICIMAB IN PATIENTS WITH DYSLIPIDEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
昂戈瑞西單抗在血脂異?；颊咧械寞熜c安全性：隨機對照試驗的系統(tǒng)評價與薈萃分析

Basel Abdelazeem

北京時間：00:00
SAFETY AND EFFICACY OF SEQUENTIAL HIGH INTENSITY LIPID-LOWERING (SHILL) THERAPY FOR ATTAINMENT OF LDL-C GOAL AFTER ACUTE CORONARY SYNDROMES
序貫高強度降脂療法在急性冠狀動脈綜合征后達(dá)到低密度脂蛋白膽固醇目標(biāo)的安全性與有效性

A. K. Pradhan

1576. Complex Clinical Cases: Cardiovascular Disease Prevention 12
北京時間：00:00
UNVEILING FAMILIAL SITOSTEROLEMIA: A SILENT CULPRIT BEHIND HYPERLIPIDEMIA IN AN ASYMPTOMATIC 28 YEAR-OLD MALE
揭示家族性谷固醇血癥：一名無癥狀28歲男性高脂血癥背后的隱匿元兇

K. Arora

361. What is the Risk of Lowering Cholesterol? Addressing Patient Concerns Regarding Lipid-Lowering Therapies
北京時間：01:18
Lipid-Lowering Therapies and HbA1c: Will Lowering My Cholesterol Give Me Diabetes?
降脂治療與糖化血紅蛋白：降低膽固醇會讓我得糖尿病嗎？

Erica Sarah Spatz

北京時間：01:28
Supplements and Cholesterol: What is the Role of OTCs in Lipid Management?
補充劑與膽固醇：非處方藥在血脂管理中的作用是什么？

Luke Laffin

1588. Cardiovascular Disease Prevention 13
北京時間：01:30
BEYOND STATINS IN ACUTE CORONARY SYNDROME—AN UPDATED META-ANALYSIS ON PCSK9 INHIBITORS AND THEIR IMPACT ON LIPID CONTROL, PLAQUE BURDEN, AND CLINICAL OUTCOMES
超越他汀，聚焦急性冠狀動脈綜合征——關(guān)于PCSK9抑制劑及其對血脂控制、斑塊負(fù)荷和臨床結(jié)局影響的最新薈萃分析

A. Singla

北京時間：01:30
LDL CHOLESTEROL AND CARDIOVASCULAR RISK ACROSS OBESITY AND METABOLIC SYNDROME PHENOTYPES: INSIGHTS FROM THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
低密度脂蛋白膽固醇與心血管風(fēng)險在肥胖及代謝綜合征不同表型中的差異：來自多民族動脈粥樣硬化研究的見解

Beshoy Iskander

北京時間：01:30
EFFICACY OF INCLISIRAN FOR MORTALITY AND CARDIOVASCULAR EVENT PREVENTION ON PATIENTS WITH ELEVATED LDL CHOLESTEROL: AN UPDATED META-ANALYSIS
英克司蘭對低密度脂蛋白膽固醇升高患者死亡率和心血管事件預(yù)防的有效性：一項更新的薈萃分析

Arthur Petrucci

366. Investigative Horizons III
北京時間：03:21
Durability Of Enlicitide For Lipid Lowering: On-treatment Analysis Of Data From CORALreef Lipids And CORALreef HeFH Trials
Enlicitide降脂的持久性：來自CORALreef Lipids和CORALreef HeFH試驗的治中數(shù)據(jù)分析

Ann Navar

POCKETIN 將挑選重點研究，就已發(fā)布結(jié)果邀請專家陸續(xù)解讀

POCKETIN接受投稿，我們將為撰稿作者提供該研究的過往詳細(xì)資料，資料包括：原文、演講幻燈、官方新聞、演講視頻等素材。并根據(jù)稿件質(zhì)量支付稿費。

稿件將發(fā)表在POCKETIN、心關(guān)注微信公眾號上，并發(fā)表在國際期刊《翳望》（ISSN 2709-9105）上。同時，稿件將作為供稿提供給合作單位。

投稿請聯(lián)系：zhengsisi@medicaltelescope.cn 鄭思思

如發(fā)現(xiàn)文內(nèi)有誤請聯(lián)系我們

來源：ACC.26

POCKETIN

ACC.26

由蘇州工業(yè)園區(qū)東方華夏心血管健康研究院和醫(yī)望共同發(fā)起的POCKETIN項目將依托人工智能學(xué)術(shù)跟蹤系統(tǒng)，為全國廣大心血管醫(yī)師帶來及時全面的報道。

項目得到了醫(yī)師報、梅斯醫(yī)學(xué)、365醫(yī)學(xué)網(wǎng)、健康界、中華醫(yī)學(xué)信息導(dǎo)報、心關(guān)注、醫(yī)心、嚴(yán)道醫(yī)聲網(wǎng)等單位的大力支持。

▼更多精彩內(nèi)容，請長按二維碼▼

1. 相關(guān)學(xué)術(shù)信息由醫(yī)望自主研發(fā)的人工智能學(xué)術(shù)跟蹤機器人提供。

2. 相關(guān)學(xué)術(shù)信息由醫(yī)望提供的醫(yī)學(xué)翻譯機器人完成翻譯后邀請臨床醫(yī)師進(jìn)行再次校對。
3. 如有內(nèi)容上的不準(zhǔn)確請微信聯(lián)系我們（zhengsisi@medicaltelescope.cn）

4. POCKETIN引入人工智能大語言模型，攜手專業(yè)編輯團隊，開啟會議速遞全新體驗。